Analysts Set Oculis Holding AG (NASDAQ:OCS) PT at $41.50

Shares of Oculis Holding AG (NASDAQ:OCS) have earned an average recommendation of “Moderate Buy” from the nine analysts that are presently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating and eight have issued a buy rating on the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $41.50.

OCS has been the topic of several research analyst reports. Lifesci Capital initiated coverage on Oculis in a research note on Wednesday, December 3rd. They set an “outperform” rating and a $55.00 price objective on the stock. Bank of America reduced their price target on shares of Oculis from $30.00 to $29.00 and set a “buy” rating on the stock in a research report on Thursday, November 13th. Wall Street Zen raised shares of Oculis from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. Chardan Capital reiterated a “buy” rating and set a $51.00 price objective on shares of Oculis in a research note on Tuesday, November 11th. Finally, Stifel Nicolaus lifted their target price on Oculis from $35.00 to $40.00 and gave the company a “buy” rating in a research note on Friday, December 19th.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in OCS. China Universal Asset Management Co. Ltd. increased its position in Oculis by 100.0% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 2,000 shares of the company’s stock worth $40,000 after buying an additional 1,000 shares during the period. Aventura Private Wealth LLC bought a new position in shares of Oculis during the fourth quarter worth about $80,000. Bosun Asset Management LLC acquired a new stake in shares of Oculis in the 2nd quarter worth about $378,000. Marshall Wace LLP bought a new stake in Oculis in the 2nd quarter valued at about $393,000. Finally, Geode Capital Management LLC boosted its stake in Oculis by 27.7% during the 2nd quarter. Geode Capital Management LLC now owns 29,436 shares of the company’s stock valued at $571,000 after purchasing an additional 6,384 shares during the period. 22.30% of the stock is currently owned by institutional investors.

Oculis Stock Up 3.6%

NASDAQ:OCS opened at $28.48 on Thursday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.47 and a current ratio of 4.47. The company has a market capitalization of $1.49 billion, a price-to-earnings ratio of -11.30 and a beta of 0.28. Oculis has a one year low of $14.00 and a one year high of $29.36. The stock has a 50-day simple moving average of $22.80 and a 200 day simple moving average of $20.08.

Oculis (NASDAQ:OCS) last announced its quarterly earnings data on Monday, November 10th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.50) by $0.10. The firm had revenue of $0.31 million for the quarter, compared to analysts’ expectations of $0.23 million. Oculis had a negative return on equity of 80.82% and a negative net margin of 12,915.42%. Sell-side analysts predict that Oculis will post -2.09 EPS for the current fiscal year.

About Oculis

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.